PIMS-E, a Subsidiary of PureIMS, Announces Results of a Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhaler for Early Intervention in Allergic Reactions and Anaphylaxis
PIMS-E, a subsidiary of PureIMS, completes Dosing in Phase 1 Clinical Trial of Epinephrine Cyclops™, a Dry Powder Inhalation Device for Early Intervention in Allergic Reactions and Anaphylaxis